Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Hematological Disorders

Biogen’s Aduhelm; FDA Approves SanofiR...

Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limit...

Feb 08, 2022

what-is-the-future-of-beta-thalassemia-market
Beta Thalassemia Treatment – Insights Into the Challenges & Solutions

Beta Thalassemia (β-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin ana...

Find More
oncological-drugs-to-be-launch-in-2022
Most Promising Oncological Drugs Expected to Launch in 2022

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...

Find More
medtech-news-for-zynex-foldax-bd-ge-edwards
Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; Edwards obtains FDA approval; BD launched instrument for testing; GE acquires BK Medical; Zynex’ CM-1500; Foldax’s TRIA biopolymer heart valve

Sky receives FDA clearance to market the geko™ device for venous insufficiency and ischemia  On December 16, 2021, Sky Medical Technology Ltd, a medical device company, got approval from the US Food and Drug Administration (FDA) 510(k) to market the geko™ device for growing microcirculatory bl...

Find More

More Views & Analysis

Diffuse Large B-cell Lymphoma Highlights
Major Highlights of Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) in ASH 2021

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveIns...

Find More

Follicular Lymphoma Highlights
Major Highlights of Follicular Lymphoma (FL) in ASH 2021

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveIns...

Find More

pharma-news-for-pfizer-takeda-novartis-roche
Pfizer to acquire Arena Pharma; Takeda’s ‘Wave 2’ multiple myeloma med data; Novartis’s next-gen CAR-Ts clinical data; Roche unveils Avenio system

Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on ha...

Find More

Myelodysplastic Syndrome Key Pharma Players
Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Findings at ASH 2021

There has been limited progress in the approval of novel agents in MDS. It has been a long wait since the last approval of lenalidomide (Revlimid) – only approved for 5–10% (del 5q) MDS patients – was granted 13 years back. Since then, only two other companies, Celgene and Astex Pharma; could succeed in getting app...

Find More

ash-2021-annual-meeting-coverage
Major Highlights of ASH 2021 Annual Meeting: Stay abreast of the fresh developments!!

Blood cancers have seen tremendous advancements in the past few years due to the dedication of researchers pulling out all the stops to churn out therapeutic innovations intended to be of service to suffering patients. These experimentations and their upshots are always brought to us through various platforms, the ...

Find More

pharma-news-for-bluebird-bio-fda-twist-bioscience-sosei-heptares
Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M

Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved in the US. The Cambridge, MA biotech declared that the FDA had accepted and given priority review for Zynteglo, its gene therapy for the rare blood disorder beta-thalassemia. The announcement sets up an expe...

Find More

In the past few years, online buying has become the easiest way to purchase products and services. T.....

Find More

Diabetic macular edema (DME) is an eye disease in which there is fluid buildup in the macula. Even t.....

Find More

Dry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....

Find More

Uremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic it.....

Find More

Lamellar Ichthyosis (LI) is an autosomal recessive congenital Ichthyosis (ARCI), which mainly affect.....

Find More

Asthma is a chronic disease of the air passages characterized by inflammation and narrowing of the a.....

Find More